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LO-F.01 COST VARIATION IN
LAPAROSCOPIC CHOLECYSTECTOMY
AND ASSOCIATION WITH OUTCOMES
ACROSS A SINGLE HEALTH
SYSTEM: IMPLICATIONS FOR
STANDARDIZATION AND IMPROVED
RESOURCE UTILIZATION
D. Brauer, R. C. Fields, W. G. Hawkins, S. M. Strasberg,
L. M. Brunt, N. Mercurio, D. P. Jaques, B. L. Hall
Barnes-Jewish Hospital, Washington University School Of
Medicine, St. Louis, MO
Background: Payers and regulatory bodies are increasingly
placing emphasis on cost containment, quality/outcome
measurement, and transparent reporting. Significant cost
variation occurs in many operative procedures without a
clear relationship with outcomes. Clear cost-benefit associa-
tions will be necessary to justify increased expenditures in
the era of bundled payment structures.
Hypothesis: Operating room (OR) supply cost variation in
laparoscopic cholecystectomy (LCCK) is not associated with
improved outcomes.
Methods: All LCCKs performed within a single health
system over a one-year period were analyzed for OR supply
cost. Results were obtained for individual surgeons and
system hospitals. Costs were correlated with NSQIP
outcomes.
Results: From July, 2013–June, 2014, 2,178 LCCKs were
performed by 55 surgeons at 7 hospitals. The median case
OR supply cost was $513 ± 156. There was significant vari-
ation in cost between individual surgeons, hospitals, and
within an individual surgeon’s practice (Figure). There was
no significant correlation between cost and individual
surgeon volume, hospital, or NSQIP outcomes. The majority
of cost variation was explained by selection of trocar and clip
applier constructs.
Conclusions: Significant case OR cost variation is present in
LCCK across a single health system. Differences in cost are
not associated with individual surgeon volume or hospital and
there is no clear association between increased cost and
NSQIP outcomes. Placed within the larger context of overall
cost, opportunity exists for OR case standardization and
savings with no obvious risk for a reduction in quality of care,
which is critical in the era of bundled payment structures.
[Correction added on 24 February 2015, after online
publication. D. Brauer was added to the list of authors.]
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LO-F.02 ANALYSIS OF LYMPH NODE
POSITIVE PATIENTS IN SURGICALLY
TREATED INTRAHEPATIC
CHOLANGIOCARCINOMA: A REVIEW
OF THE NATIONAL CANCER DATABASE
Z. Jutric, C. W. Johnston, H. M. Hoen, P. H. Newell,
M. A. Cassera, C. W. Hammill, R. F. Wolf, P. D. Hansen
Providence Portland Cancer Center, Portland, OR
Introduction: The role of routine lymphadenectomy in the
surgical treatment of intrahepatic cholangiocarcinoma (ICC)
has been poorly defined. Recent studies have recommended
consideration of lymphadenectomy given its prognostic
implications. We aim to define predictive indicators of sur-
vival in patients with positive lymph nodes.
Methods: The National Cancer Data Base (NCDB) was
queried for patients who underwent surgical resection for
ICC between 1998 and 2011. Single predictor univariate
analyses were performed on 23 variables including demo-
graphics, tumor characteristics, surgery outcomes and adju-
vant therapy details. Both single predictor univariate and
multivariate Cox proportional hazards survival analysis were
then performed on 160 patients identified to have positive
lymph nodes.
Results: Of 823 patients with complete data, 57% had at
least one lymph node examined. Median survival for lymph
node negative patients was 37 months versus 15 months for
lymph node positive patients, results shown. Other univariate
factors associated with decreased survival include male sex,
urban location, tumor size, grade and positive margin status.
In lymph node positive patients, multivariate analysis
showed poorer survival in the patients not receiving chemo-
therapy or radiation (HR 1.43, p = .006), tumor size >5 cm
compared to <5 cm (p = .018), and older age (p < .0001).
Lymph node positive patients <age 45 had a median survival
of 27 months.
Conclusions: Overall survival in most ICC patients with
lymph node metastases is limited. Adjuvant therapy should
be considered in these patients. Strategies to improve lymph
node staging deserve further study, as many of these patients
may not benefit from resection.
LO-F.03 NATURAL HISTORY AND
TREATMENT TRENDS IN
HEPATOCELLULAR CARCINOMA
SUBTYPES: INSIGHTS FROM A
NATIONAL CANCER REGISTRY
P. L. Jernigan, K. Wima, D. J. Hanseman, R. S. Hoehn,
A. Ertel, E. Midura, I. M. Paquette, S. A. Ahmad,
S. A. Shah, D. E. Abbott
Department Of Sugery, University Of Cincinnati School Of
Medicine, Cicinnati, OH
Introduction: Histopathological advancements have
enabled more sophisticated characterization of hepatocellu-
lar carcinoma (HCC), but the clinical significance of these
distinctions is incompletely understood. Our aim was to
investigate pathologic and treatment differences between
HCC variants.
Methods: The American College of Surgeons National
Cancer Data Base (1998–2011) was queried to identify 784
patients with surgical management of six HCC subtypes
(1.8% of all HCC patients): fibrolamellar (FL, n = 206), scir-
rhous (Sc, n = 29), spindle cell (Sp, n = 20), clear cell (CC,
n = 169), mixed type (M, n = 291), and trabecular (T,
n = 69). Chi-square, Kaplan-Meier and Cox regression
analysis were used to identify associations between demo-
graphic, tumor and treatment-specific variables and clinical
outcomes, namely overall survival (OS).
Results: Patients with FL-HCC were younger than other
variants (median age 27 vs. 54–61, p < 0.001), more com-
monly female (56.3%, p < 0.001), and less likely to receive
a transplant (3.66%, p < 0.001). Patients with FL- and
Sp-HCC presented more frequently with larger tumors
(>5 cm, p < 0.001) and node-positive disease (p < 0.001).
Median OS (years) of the six subtypes was: FL 2.99 (CI
2.08–4.55), Sc 4.12 (1.47–7.01), Sp 0.56 (0.13–1.04), CC
2.99 (2.08–4.55), M 2.22 (1.61–2.7), and T 2.91 (1.88–
8.86). On multivariate analysis, better OS was associated
with FL-HCC, lower pathologic stage, node-negative
disease, and liver transplant (Table 1). Eighty-six patients
(11%) received adjuvant therapy, which was not associated
with better OS.
Conclusion: These data represent the largest series of rec-
ognizable HCC variants, demonstrating distinct differences
in presentation and natural history. These findings can help
clinicians and patients discuss treatment decisions and
prognosis for rare clinical entities.
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LO-F.04 UNDERSTANDING DRIVERS OF
COST VARIATION FOR EPISODES OF
CARE AMONG PATIENTS UNDERGOING
HEPATOPANCREATOBILIARY SURGERY
G. Spolverato, A. Ejaz, N. Ahuja, K. Hirose,
M. A. Makary, C. L. Wolfgang, M. J. Weiss, J. Cameron,
T. Pawlik
Johns Hopkins Hospital, Baltimore, MD
Background: Understanding factors associated with vari-
ation in procedure-related costs may help identify means to
increase savings. We sought to define potential variation in
hospital charges associated with hepatopancreatobiliary
(HPB) surgery.
Methods: Patients who underwent a HPB procedure
between 2009–2013 were identified. Perioperative morbidity
was ascertained through ICD-9 codes. Total hospital
charges were tabulated for room&board, surgical/anesthesia
services, medications, laboratory/radiology services, and
other charges.
Results: 2,545 patients underwent either a pancreas(66.8%)
or liver/biliary(33.2%) resection. Mean total charges
for all patients were $42,357 ± $33,745(pancreas: $46,352 ±
$34,932 vs. liver: $34,303 ± $29,639;P < 0.001). Major
morbidity(pancreas, range: 7%-18%; liver, range: 9%-
18%) and observed : expected(O : E) length-of-stay(LOS)
(pancreas, range: 0.67–1.64; liver, range: 1.06–3.35) varied
among providers(both P < 0.001). While a periopera-
tive complication resulted in increased total hospital
charges(complication: $66,401 ± $55,124 vs. no complica-
tion: $39,668 ± $29,250;P < 0.001), total charges remained
variable even among patients who did not experience a
complication(P < 0.001). For example, mean total charges
for a pancreaticoduodenectomy ranged from $41,413-
$49,543 vs. $29,376-$43,420 for a partial hepatectomy
(Figure). Surgeons within the lowest quartile of O : E LOS
had lower total charges($33,879 ± $27,398) versus surgeons
in the highest quartile($49,498 ± $40,971)(P < 0.001).
Surgeons with the highest O : E LOS had higher across-the-
board charges (operating room, highest quartile:
$10,514 ± $4,496 vs. lowest quartile: $7,842 ± $3,706;
medication, highest quartile: $1,796 ± $3,799 vs. lowest
quartile: $925 ± $2,211; radiology, highest quartile:
$2,494 ± $4,683 vs. lowest quartile: $1,424 ± $3,247;
laboratory, highest quartile: $4,236 ± $5,991 vs. lowest
quartile: $3,028 ± $3,804; all P < 0.001).
Conclusions: After accounting for in-hospital complica-
tions, total mean hospital charges for HPB surgery remained
variable by case type and provider. While the variation in cost
was associated with LOS, provider-level differences in
across-the-board charges were also noted.
LO-F.05 AN ECONOMIC ANALYSIS OF
PANCREATICODUODENECTOMY:
SHOULD COSTS DRIVE CONSUMER
DECISIONS?
T. B. Tran, M. M. Dua, D. J. Worhunsky, G. A. Poultsides,
J. A. Norton, B. C. Visser
Stanford University School Of Medicine, Stanford, CA
Background: Consumer groups campaign for cost transpar-
ency believing that patients will select hospitals accordingly.
The aim of this study was to determine whether the “cost” of
a Whipple might be considered in choosing a hospital.
Methods: Using Nationwide Inpatient Sample Database,
we analyzed charges for patients who underwent pancreati-
coduodenectomy (PD) from 2000–2010. Outcomes were
compared between high volume hospitals (HVH, >20/yr) and
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low volume hospitals (LVH). The relationship of inflation-
adjusted charges and outcomes were stratified by uncompli-
cated PD (length of stay <14 days) vs complicated PD (>14
days).
Results: A total of 15,599 PD were performed in 1,186
hospitals at a median cost of $87,444 (IQR $60,015-
$144,869). While only 94 (8%) hospitals performed >20
PD/year, 57% of all PD were performed in these HVH. HVH
had shorter hospital stay (11 vs 15 days, p < 0.001) and
mortality (3% vs 7.6%, p < 0.001). PD performed at LVH
had higher median charges compared to HVH ($97,923 vs.
$81,581, p < 0.001). The cost of uncomplicated PD was sig-
nificantly lower than a complicated PD ($67,238 (IQR
51,112–91,401) vs $138,325 (IQR 95,206–224,919),
p < 0.001). When comparing uncomplicated PD between
HVH and LVH, the median cost was very similar ($67,389 vs
$66,922). Among uncomplicated PD, a multivariate analysis
controlling for demographics and co-morbidities revealed
that cost did not affect the risk of mortality (OR 1).
Conclusions: The cost of a Whipple (even uncomplicated)
remains surprisingly variable. PD at HVH are associated
with better outcomes, which is reflected in lower charges.
But ultimately, patients should choose volume over price.
LO-F.06 THE IMPACT OF
PERIOPERATIVE BLOOD TRANSFUSION
ON SHORT-TERM OUTCOMES
FOLLOWING PANCREATECTOMY:
AN ANALYSIS FROM THE AMERICAN
COLLEGE OF SURGEONS NATIONAL
SURGICAL QUALITY IMPROVEMENT
PROGRAM (ACS-NSQIP)
J. Hallet1,2, A. L. Mahar3, M. Tsang2, C. H. Law1,2,
N. G. Coburn1,2, P. J. Karanicolas1,2
1Division Of General Surgery, Sunnybrook Health Sciences
Centre – Odette Cancer Centre, Toronto, ONTARIO;
2Department Of Surgery, University Of Toronto, Toronto,
ONTARIO; 3Department Of Public Health Sciences,
Queen’s University, Kingston, ONTARIO
Background: While perioperative red blood cell transfu-
sions (RBCT) are associated with worse outcomes in
colorectal surgery, their impact following pancreatectomy
remains unclear. We sought to examine the association
between RBCT and post-operative morbidity following pan-
createctomy.
Methods: Using the ACS-NSQIP database, we identified
patients undergoing elective pancreatectomy from 2006 to
2012. Patients missing data on key variables were excluded.
We compared post-operative morbidity and length of stay
based on RBCT status using univariate and multivariate
analyses. A sensitivity analysis was conducted excluding
patients with higher baseline risk for RBCT.
Results: From 21,132 pancreatectomies, we included
14,322 patients of whom 1624 (11.3%) received RBCT.
Major morbidity (34.9% Vs. 21.6%; p < 0.0001) and mortal-
ity (15.7% Vs. 11.5%; p < 0.0001) were higher, and median
length of stay was prolonged (15.7 Vs. 11.5 days; p < 0.0001)
with RBCT. After adjustment for baseline characteristics
including comorbidities, malignant diagnosis, procedure,
and operative time, RBCT was independently associated
with increased major morbidity (Relative Risk – RR 1.45;
p < 0.0001), post-operative infections (RR 1.30; p < 0.001),
thrombo-embolic events (RR 1.41; p = 0.01), cardiac events
(RR 2.41; p < 0.0001), respiratory failure (RR 2.60;
p < 0.0001), and mortality (RR 2.51; p < 0.0001). Length of
stay was prolonged with RBCT (adjusted mean estimate
1.22; p < 0.0001). Excluding patients with higher baseline
risk of RBCT did not substantially alter the results.
Conclusion: Perioperative RBCT is independently associ-
ated with worse short-term outcomes and prolonged length
of stay following pancreatectomy. This observation holds
true in patients with lower baseline risk of RBCT. Compre-
hensive multidisciplinary strategies to minimize and ration-
alize the use of RBCT are warranted.
LO-F.07 RESECTION OF COLORECTAL
CANCER LIVER METASTASES IN THE
SETTING OF EXTRAHEPATIC DISEASE;
RESULTS FROM A RANDOMIZED TRIAL
EVALUATING THE EFFECT OF PET-CT
P. E. Serrano1, C. Moulton2, C. Gu1, C. H. Law3, L. Ruo1,
K. Y. Gulenchyn1, D. Quan4, R. Fairfull Smith5,
D. W. Jalink6, M. Husien7, J. A. Julian1, M. N. Levine1,
S. Gallinger2
1McMaster University, Hamilton, ON; 2University Health
Network, University Of Toronto, Toronto, ON; 3Sunnybrook
Health Sciences Centre And Odette Cancer Centre,
Toronto, ON; 4London Health Sciences Centre, London,
ON; 5The Ottawa Hospital, Ottawa, ON; 6Cancer Centre
Of Southeastern Ontario, Kingston, ON; 7Grand River
Regional Cancer Centre, Kitchener, ON
Introduction: Selected patients with colorectal cancer liver
metastases (CRLM) and extra-hepatic disease (EHD) are
considered for curative surgery. The main objective of this
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study was to evaluate the oncologic outcomes of patients
with specified CRLM-EHD vs. CRLM-only and to deter-
mine the effect of PET-CT on disease-free (DFS) and overall
survival (OS).
Methods: This is a sub-study of a randomized trial studying
the effect of PET-CT before liver resection on surgical man-
agement of CRLM with or without EHD (limited to specified
resectable metastases: portal lymph nodes/lung/local recur-
rence) in patients with resected colorectal cancer from 2005–
2013. Survival data adjusted for PET-CT was analyzed using
standard statistics.
Results: From 404 patients in the trial, 25 had EHD at
randomization [14 PET-CT group and 11 control (no
PET-CT)]. The most common EHD-site was lung (n = 18).
All EHD sites known at randomization were resected
(PET-CT and control group). After median follow-up of
36-months, median DFS for CRLM-EHD was 5.9-months
(95%CI: 3.6–11.7) and 16.2-months (95%CI: 13.7–18.9) for
CRLM-only [unadjusted-HR: 3.03 (95%CI: 2.00–4.59)]; the
estimated OS was similar between groups [36.7-months
(95%CI: 26.8–43.4) vs. 40.7-months (95%CI: 40.5–57)
respectively; unadjusted-HR: 1.68 (95%CI: 0.98, 2.89)].
After adjusting for the use of PET-CT, DFS for CRLM-EHD
remained significantly worse compared to CRLM-only
without significant differences in the adjusted OS.
Conclusions: Metastasectomy for specified and limited
CRLM-EHD is associated with similar OS to CRLM-only
despite a lower DFS. The use of PET-CT prior to complete
metastasectomy did not affect the time to recurrence or the
OS of patients with CRLM-EHD.
LO-F.08 TIMING, INCIDENCE, AND
RISK FACTORS ASSOCIATED WITH
UNPLANNED POSTOPERATIVE
HOSPITAL READMISSIONS IN THE
HEPATO-PANCREATICO-BILIARY
PATIENTS
G. C. Edwards1, L. Du1, J. R. Miller2, J. Ehrenfeld1,
H. R. Mir1, Y. Shyr1, A. A. Parikh1, N. B. Merchant1,
K. Idrees1
1Vanderbilt University Medical Center, Nashville, TN;
2Meharry Medical College, Nashville, TN
Introduction: As part of the Affordable Care Act, the Hos-
pital Readmissions Reduction Program (HRRP), has started
to impose financial sanctions on hospitals with increased
readmission rates. The purpose of this study is to define the
incidence and identify peri-operative factors associated with
30 and 90-day readmission after hepatic (HR) and pancreatic
resections (PR).
Methods: HR and PR patients were retrospectively
reviewed over an 8 year period. Pre-operative factors [patient
demographics, ASA class, Charlson Comorbidity Index,
Elixhauser Comorbidity Index], intra-operative factors [Sur-
gical Apgar Score (SAS), operative duration] and post-
operative factors [postoperative major complications (PMC),
hospital length of stay (LOS), ICU LOS, discharge disposi-
tion] were evaluated. Multivariable Cox regression (MVR)
analysis was used to examine associations for hospital
readmission.
Results: 30 and 90-day readmission rates in 878 patients are
shown in the table. By MVR, PMC (HR = 8.9, 95%,
p = 0.0003), PR (HR = 2.3, p = 0.006), ICU LOS (HR = 1.1,
p = 0.02) and SAS (HR = 0.75, p = 0.02) were associated
with 30-day readmission. PMC (HR = 7.5, p = 0.0001) and
PR (HR = 2.1, p = 0.007) were also associated with 90-day
readmission. In patients without complications, ICU LOS
(HR = 7.0, p = 0.03), PR (HR = 2.4, p = 0.006) and SAS
(HR = 0.7, p = 0.04) were independently associated with
30-day readmission while only PR (HR = 2.1, p = 0.007) was
associated with 90-day readmission.
Conclusions: The 90-day readmission rate in HPB patients
remains high (18.8%) and the majority of readmissions
(88.8%) occur within 30 days of discharge. Identifying
factors associated with an increased risk of readmission is
critical in the development of interventions and resource
utilization to help reduce unplanned readmissions and
decrease costs within this population.
LO-F.09 MISSING THE OBVIOUS:
PSYCHOSOCIAL OBSTACLES IN
VETERANS WITH HCC
K. J. Hwa1,2, M. M. Dua1,2, S. M. Wren1,2, B. C. Visser1,2
1Stanford University School Of Medicine, Stanford, CA;
2Palo Alto Veterans Affairs Hospital, Palo Alto, CA
Introduction: Socioeconomic disparities in patients with
hepatocellular carcinoma (HCC) influence medical access
and treatment. However, in addition to socioeconomic barri-
ers, the veteran population suffers from significant psycho-
social obstacles. This study identifies the often overlooked
social challenges that veterans face while undergoing treat-
ment for HCC.
Methods: We retrospectively reviewed prospectively gath-
ered data regarding social/behavioral hardships for 100 vet-
erans at the Palo Alto VA who had been treated for HCC
between 2009–2014 (50 consecutive patients who underwent
resection and 50 treated with intra-arterial therapy).
Results: Substance abuse history was identified in 96%,
with 34% actively abusing alcohol or drugs. Half were unem-
ployed. Most patients survived on very limited income
(median $1340/mo, IQR $900–2125); 36% on <$1000/mo,
37% between $1001–2000/mo, and 27% with >$2000/mo.
Fully, 37% were homeless at time of index treatment, which
was more common in those with the lowest income (62% of
<$1K/mo group, 32% of $1–2K/mo group, and 6% of
>$2K/mo group, p < 0.05). Psychiatric illness was present in
64/100 (64%) patients; among these the majority (59/64,
92%) received ongoing psychiatric treatment. The top two
diagnoses were depression and PTSD. Fifty-one percent of
all patients had been incarcerated. Transportation was pro-
vided to 23% of patients who would otherwise have been
unable to attend medical appointments.
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Conclusions: Psychiatric disease and substance abuse are
highly prevalent among veterans with HCC. Most patients
are surviving on very meager income. These profound socio-
economic and psychosocial problems must be recognized
when providing care for HCC to this population to provide
adequate treatment and surveillance.
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LO-G.01 TAUROURSODEOXYCHOLIC
ACID ALLEVIATES ISCHEMIA/
REPERFUSION INJURY IN STEATOTIC
MOUSE LIVER
C. D. Anderson, J. Zhang, N. Singh, W. Dorsett-Martin,
T. M. Earl
University Of Mississippi Medical Center, Jackson, MS
Background: Tauroursodeoxycholic acid (TUDCA)
decreases endoplasmic reticulum (ER) stress, autophagy, and
cell death in cultured rat hepatocytes. We hypothesized that
TUDCA could reduce the injury caused by total warm
ischemia reperfusion (WIR) in steatotic mouse liver.
Methods: Male ob/ob mice underwent 100% hepatic warm
ischemia by clamping the portal triad for 30 minutes. For the
experiment group, 200 mg/kg TUDCA was injected IP 1
hour before the surgery. Animals were sacrificed at 12 hours
and 48 hours after reperfusion. Quantitative real time PCR
measured ER stress markers such as C/EBP homologous
protein (CHOP), glucose regulated protein 78 (GRP78),
protein kinase dsRNA-dependent-like ER kinase (PERK),
and activating transcription factor-6 (ATF6). Western blot
examined autophagy marker microtubule-associated protein
1 light chain 3 (LC3 II). ELISA determined interleukine-6
(IL6) levels (liver and serum).
Results: Compared to controls, WIR increased ER stress in
the liver [CHOP (∼3 fold, p = 0.004), GRP78 (∼4 fold,
p = 0.001), PERK (∼2 fold, p = 0.005), and ATF6 (∼1.5 fold,
p = 0.004)] at 12 but not 48 hours. LC3 II protein levels were
increased at both 12 (∼3 fold, p = 0.019) and 48 hours (∼4 fold,
p = 0.025). Serum IL6 levels were increased at 12 (∼40 fold,
p = 0.034) and 48 hours (∼33 fold, p = 0.034). TUDCA treat-
ment decreased LC3 II at 12 (p = 0.018) and 48 hours
(p = 0.034), decreased serum IL6 at 12 (p = 0.025) and 48
hours (p = 0.025), and improved animal survival (median 26
hours vs 41 hours, p = 0.02). ER stress levels were not
changed.
Conclusion: TUDCA improves survival and reduces the
inflammation following WIR in steatotic liver through a
non-ER stress pathway.
LO-G.02 CHARACTERIZATION OF A
PORCINE MODEL FOR ASSOCIATING
LIVER PARTITION AND PORTAL VEIN
LIGATION FOR STAGED
HEPATECTOMY (ALPPS)
K. P. Croome, S. A. Mao, J. M. Glorioso, S. L. Nyberg,
D. M. Nagorney
Mayo Clinic, Rochester, MN
Background: Publications using the ALPPS procedure have
demonstrated a future liver remnant(FLR) growth of
40–160% in only 6–9 days. The present study aimed to
develop and describe the first large animal model of ALPPS
that can be used for future studies.
Methods: A total of 13 female domestic swine were studied.
ALPPS stage 1 (portal vein division and parenchymal
transection) was followed by ALPPS stage 2 (completion left
extended hepatectomy) 7 days later. An abdominal CT scan
was performed immediately prior to ALPPS stage 1 surgery
and again 7 days later to assess hypertrophy immediately
prior to ALPPS stage 2 surgery. Blood samples as well as
tissue analysis were performed.
Results: On CT volumetric analysis mean size of the FLR
prior to ALPPS stage 1 was 21.4 ± 1.8% and 39.8 ± 4.6%
prior to ALPPS stage 2. Median degree of hypertrophy was
74.5% with a median kinetic growth rate of 10.6% per day.
Liver weights at autopsy correlated well with CT volumetric
analysis(p = 0.65). There was no significant difference in
mean lab values (AST,ALT,ammonia,INR or bilirubin) from
baseline until immediately prior to ALPPS stage 2. Post
ALPPS stage 2 there was a significant increase in INR from
baseline 1.1 ± 0.1 and 1.6 ± 0.1 (p = 0.005), respectively. No
post-operative deaths secondary to liver failure were
observed.
Conclusion: The present study describes the first reproduc-
ible large animal model of the ALPPS procedure. Degree of
hypertrophy and kinetic growth rate were similar to that which
has been demonstrated in human publications. This model
will be valuable as future laboratory studies are performed.
LO-G.03 PREOPERATIVE ANAEMIA AND
POSTOPERATIVE OUTCOMES AFTER
HEPATECTOMY: A RETROSPECTIVE
COHORT STUDY
S. Tohme, P. Varley, M. Khreiss, A. Tsung
University Of Pittsburgh, Pittsburgh, PA
Background: Preoperative anemia is associated with
adverse outcomes after surgery in general but outcomes after
hepatectomy specifically are not well established. We aimed
to assess the effect of preoperative anemia on 30-day post-
operative morbidity and mortality in patients undergoing
major hepatectomies.
Methods: All elective hepatectomies for the period 2005–
2012 recorded in the NSQIP database were evaluated. We
selected to study partial lobectomies, total left, total right,
and trisegmentectomies and exclude minor procedures. We
obtained anonymized data for 30-day mortality and morbid-
ity, demographics, and preoperative and perioperative risk
factors. We used multivariate logistic regression to assess the
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